Stanbio’s enzymatic Beta Hydroxybutyrate (β-HB) assay produces an accurate and quantitative value that is specific to the β-HB ketone. These performance qualities are making β-HB the new clinical diagnostic standard of care for ketone testing.
Currently, a major U.S. news magazine ranking shows that 15 of the top 25 diabetes and endocrinology hospitals are using a form of Stanbio’s β-HB assay. In the U.S., more than 900 hospitals have implemented β-HB testing to better serve their patients. Survey results from a widely recognized laboratory reporting organization show that adoption of the Stanbio β-HB chemistry assay is up 200% from 2011 to 2013. In 2011, 9% of surveyed facilities reported using a form of the β-HB assay for ketone testing. The percentage has grown to 27% in 2013.
“We’re happy about the increasing use of β-HB in hospital labs,” said Stanbio Laboratory General Manager, Gilbert A. Mejia. “This escalating demand is also improving the way we’re presenting the open-channel reagent to healthcare organizations. For example, we’ve recently had widely recognized Ph.D.’s and physician champions help with our internal product training so we can articulate the efficacy of the test more concisely. We’re seeing the benefits of this new approach as more and more hospital organizations are inquiring about and validating the assay,” Mejia added.
Benefits of the Stanbio β-HB assay were recently on display at the Advanced Pediatric Emergency Medicine Assembly in New York, the SEMPA 360 (Society of Emergency Medicine® Physician Assistants) show in New Orleans and the Southeastern Critical Care Summit at the Emory University School of Medicine in Atlanta.